Table 1 Clinical pathological characteristics of ESCC patients receiving anti-PD1 plus chemotherapy
Characteristics (n = 64) | N (%) |
|---|---|
Age (years)a | |
≤ 62 | 34 (53.1) |
> 62 | 30 (46.9) |
ECOG-PS | |
0 | 20 (31.3) |
1 | 44 (68.7) |
Gender | |
Male | 50 (78.1) |
Female | 14 (21.9) |
Smoking | |
Yes | 37 (57.8) |
No | 27 (42.2) |
T stage | |
T1–T2 | 8 (12.5) |
T3–T4 | 56 (87.5) |
N stage | |
N0 | 20 (31.3) |
N1–N2 | 44 (68.7) |
Clinical stage | |
II | 19 (29.7) |
III | 33 (51.6) |
IV | 12 (18.7) |
CAP/NCCN pathological tumor regression grade | |
0 | 27 (42.2) |
1 | 14 (21.8) |
2 | 11 (17.2) |
3 | 12 (18.8) |